Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Prevalence, predictors, and consequences of inappropriate empiric antimicrobial therapy for complicated urinary tract and intra-abdominal infections in Winnipeg hospitals.

Righolt CH, Lagace-Wiens P, Mahmud SM.

Diagn Microbiol Infect Dis. 2020 Jan;96(1):114891. doi: 10.1016/j.diagmicrobio.2019.114891. Epub 2019 Aug 30.

PMID:
31668828
2.

Trends in antimicrobial resistance over 10 years among key bacterial pathogens from Canadian hospitals: results of the CANWARD study 2007-16.

Lagacé-Wiens PRS, Adam HJ, Poutanen S, Baxter MR, Denisuik AJ, Golden AR, Nichol KA, Walkty A, Karlowsky JA, Mulvey MR, Golding G, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD .

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv22-iv31. doi: 10.1093/jac/dkz284.

PMID:
31505648
3.

Dramatic rise in the proportion of ESBL-producing Escherichia coli and Klebsiella pneumoniae among clinical isolates identified in Canadian hospital laboratories from 2007 to 2016.

Denisuik AJ, Karlowsky JA, Adam HJ, Baxter MR, Lagacé-Wiens PRS, Mulvey MR, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD .

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv64-iv71. doi: 10.1093/jac/dkz289.

PMID:
31505647
4.

Characterization of MRSA in Canada from 2007 to 2016.

Nichol KA, Adam HJ, Golding GR, Lagacé-Wiens PRS, Karlowsky JA, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD .

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv55-iv63. doi: 10.1093/jac/dkz288.

PMID:
31505646
5.

42936 pathogens from Canadian hospitals: 10 years of results (2007-16) from the CANWARD surveillance study.

Zhanel GG, Adam HJ, Baxter MR, Fuller J, Nichol KA, Denisuik AJ, Golden AR, Hink R, Lagacé-Wiens PRS, Walkty A, Mulvey MR, Schweizer F, Bay D, Hoban DJ, Karlowsky JA; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD .

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv5-iv21. doi: 10.1093/jac/dkz283.

PMID:
31505641
6.

Validation of the Seegene RV15 multiplex PCR for the detection of influenza A subtypes and influenza B lineages during national influenza surveillance in hospitalized adults.

LeBlanc JJ, ElSherif M, Mulpuru S, Warhuus M, Ambrose A, Andrew M, Boivin G, Bowie W, Chit A, Dos Santos G, Green K, Halperin SA, Hatchette TF, Ibarguchi B, Johnstone J, Katz K, Langley JM, Lagacé-Wiens P, Loeb M, Lund A, MacKinnon-Cameron D, McCarthy A, McElhaney JE, McGeer A, Poirier A, Powis J, Richardson D, Semret M, Shinde V, Smyth D, Trottier S, Valiquette L, Webster D, Ye L, McNeil SA.

J Med Microbiol. 2019 Jul 2. doi: 10.1099/jmm.0.001032. [Epub ahead of print]

PMID:
31264957
7.

In vitro susceptibility of urinary Escherichia coli isolates to first- and second-line empirically prescribed oral antimicrobials: CANWARD surveillance study results for Canadian outpatients, 2007-2016.

Karlowsky JA, Lagacé-Wiens PRS, Adam HJ, Baxter MR, Laing NM, Walkty AJ, Zhanel GG.

Int J Antimicrob Agents. 2019 Jul;54(1):62-68. doi: 10.1016/j.ijantimicag.2019.04.012. Epub 2019 Apr 26.

PMID:
31034938
8.

CHROMagar™ orientation urine culture medium produces matrix-assisted laser desorption ionization-time-of-flight mass spectrometry spectra misidentified as Mycoplasma arginini and Mycoplasma alkalescens.

Lagacé-Wiens PRS, Abbott AA, Karlowsky JA.

Diagn Microbiol Infect Dis. 2019 Jun;94(2):113-115. doi: 10.1016/j.diagmicrobio.2018.12.014. Epub 2019 Jan 2.

PMID:
30718158
9.

Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.

Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagacé-Wiens PRS, Walkty AJ, Noreddin A, Lynch Iii JP, Karlowsky JA.

Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2. Review.

PMID:
30712199
10.

Antimicrobial-resistant pathogens in Canadian ICUs: results of the CANWARD 2007 to 2016 study.

Denisuik AJ, Garbutt LA, Golden AR, Adam HJ, Baxter M, Nichol KA, Lagacé-Wiens P, Walkty AJ, Karlowsky JA, Hoban DJ, Mulvey MR, Zhanel GG.

J Antimicrob Chemother. 2019 Mar 1;74(3):645-653. doi: 10.1093/jac/dky477.

PMID:
30500898
11.

In Vitro Activity of Sulopenem, an Oral Penem, against Urinary Isolates of Escherichia coli.

Karlowsky JA, Adam HJ, Baxter MR, Denisuik AJ, Lagacé-Wiens PRS, Walkty AJ, Puttagunta S, Dunne MW, Zhanel GG.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01832-18. doi: 10.1128/AAC.01832-18. Print 2019 Jan.

12.

Evaluation of three MALDI-TOF mass spectrometry libraries for the identification of filamentous fungi in three clinical microbiology laboratories in Manitoba, Canada.

Stein M, Tran V, Nichol KA, Lagacé-Wiens P, Pieroni P, Adam HJ, Turenne C, Walkty AJ, Normand AC, Hendrickx M, Piarroux R, Karlowsky JA.

Mycoses. 2018 Oct;61(10):743-753. doi: 10.1111/myc.12800. Epub 2018 Jul 2.

PMID:
29893421
13.

Correction to: Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.

Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2018 May;78(7):787. doi: 10.1007/s40265-018-0910-x.

PMID:
29748749
14.

Influenza vaccine effectiveness to prevent influenza-related hospitalizations and serious outcomes in Canadian adults over the 2011/12 through 2013/14 influenza seasons: A pooled analysis from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS Network).

Nichols MK, Andrew MK, Hatchette TF, Ambrose A, Boivin G, Bowie W, Chit A, Dos Santos G, ElSherif M, Green K, Haguinet F, Halperin SA, Ibarguchi B, Johnstone J, Katz K, Lagacé-Wiens P, Langley JM, LeBlanc J, Loeb M, MacKinnon-Cameron D, McCarthy A, McElhaney JE, McGeer A, Poirier A, Powis J, Richardson D, Schuind A, Semret M, Shinde V, Smith S, Smyth D, Stiver G, Taylor G, Trottier S, Valiquette L, Webster D, Ye L, McNeil SA; Serious Outcomes Surveillance Network of the Canadian Immunization Research Network (CIRN), the Toronto Invasive Bacterial Diseases Network (TIBDN).

Vaccine. 2018 Apr 12;36(16):2166-2175. doi: 10.1016/j.vaccine.2018.02.093. Epub 2018 Mar 13.

PMID:
29548608
15.

In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008-16.

Walkty A, Adam H, Baxter M, Lagacé-Wiens P, Karlowsky JA, Hoban DJ, Zhanel GG.

J Antimicrob Chemother. 2018 Mar 1;73(3):703-708. doi: 10.1093/jac/dkx468.

PMID:
29244121
16.

Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.

Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2018 Jan;78(1):65-98. doi: 10.1007/s40265-017-0851-9. Review. Erratum in: Drugs. 2018 May 10;:.

PMID:
29230684
17.

Emerging group C and group G streptococcal endocarditis: A Canadian perspective.

Lother SA, Jassal DS, Lagacé-Wiens P, Keynan Y.

Int J Infect Dis. 2017 Dec;65:128-132. doi: 10.1016/j.ijid.2017.10.018. Epub 2017 Oct 31.

18.

Clonal Clusters and Virulence Factors of Group C and G Streptococcus Causing Severe Infections, Manitoba, Canada, 2012-2014.

Lother SA, Demczuk W, Martin I, Mulvey M, Dufault B, Lagacé-Wiens P, Keynan Y.

Emerg Infect Dis. 2017 Jul;23(7):1079-1088. doi: 10.3201/eid2307.161259.

19.

Antimicrobial susceptibility of clinical isolates of Neisseria gonorrhoeae to alternative antimicrobials with therapeutic potential.

Lagacé-Wiens PRS, Adam HJ, Laing NM, Baxter MR, Martin I, Mulvey MR, Karlowsky JA, Hoban DJ, Zhanel GG.

J Antimicrob Chemother. 2017 Aug 1;72(8):2273-2277. doi: 10.1093/jac/dkx147.

PMID:
28505331
20.

Antimicrobial susceptibility of 2906 Pseudomonasaeruginosa clinical isolates obtained from patients in Canadian hospitals over a period of 8 years: Results of the Canadian Ward surveillance study (CANWARD), 2008-2015.

Walkty A, Lagace-Wiens P, Adam H, Baxter M, Karlowsky J, Mulvey MR, McCracken M, Zhanel GG.

Diagn Microbiol Infect Dis. 2017 Jan;87(1):60-63. doi: 10.1016/j.diagmicrobio.2016.10.003. Epub 2016 Oct 7.

PMID:
28336136
21.

Characterization of isolates of Eisenbergiella tayi, a strictly anaerobic Gram-stain variable bacillus recovered from human clinical materials in Canada.

Bernard K, Burdz T, Wiebe D, Balcewich BM, Zimmerman T, Lagacé-Wiens P, Hoang LMN, Bernier AM.

Anaerobe. 2017 Apr;44:128-132. doi: 10.1016/j.anaerobe.2017.03.005. Epub 2017 Mar 7.

PMID:
28279858
22.

Frequency of MCR-1-mediated colistin resistance among Escherichia coli clinical isolates obtained from patients in Canadian hospitals (CANWARD 2008-2015).

Walkty A, Karlowsky JA, Adam HJ, Lagacé-Wiens P, Baxter M, Mulvey MR, McCracken M, Poutanen SM, Roscoe D, Zhanel GG.

CMAJ Open. 2016 Oct 26;4(4):E641-E645. doi: 10.9778/cmajo.20160080. eCollection 2016 Oct-Dec.

23.

Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.

Zhanel GG, Hartel E, Adam H, Zelenitsky S, Zhanel MA, Golden A, Schweizer F, Gorityala B, Lagacé-Wiens PR, Walkty AJ, Gin AS, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2016 Dec;76(18):1737-1757. Review.

PMID:
27909995
24.

Multifaceted antibiotic treatment analysis of methicillin-sensitive Staphylococcus aureus bloodstream infections.

Weber Z, Ariano R, Lagacé-Wiens P, Zelenitsky S.

Int J Antimicrob Agents. 2016 Dec;48(6):674-679. doi: 10.1016/j.ijantimicag.2016.09.007. Epub 2016 Oct 12.

PMID:
27789207
25.

Microbiological Trends and Antimicrobial Resistance in Peritoneal Dialysis-Related Peritonitis, 2005 to 2014.

Zelenitsky SA, Howarth J, Lagacé-Wiens P, Sathianathan C, Ariano R, Davis C, Verrelli M.

Perit Dial Int. 2017 Mar-Apr;37(2):170-176. doi: 10.3747/pdi.2016.00136. Epub 2016 Oct 13.

PMID:
27738087
26.

Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent.

Zhanel GG, Cheung D, Adam H, Zelenitsky S, Golden A, Schweizer F, Gorityala B, Lagacé-Wiens PR, Walkty A, Gin AS, Hoban DJ, Karlowsky JA.

Drugs. 2016 Apr;76(5):567-88. doi: 10.1007/s40265-016-0545-8. Review.

PMID:
26863149
27.

Quintessential Culture-Negative Endocarditis.

Keynan Y, MacKenzie L, Lagacé-Wiens P.

Can J Cardiol. 2016 Mar;32(3):395.e9-e10. doi: 10.1016/j.cjca.2015.05.027. Epub 2015 Jun 17.

PMID:
26342845
28.

Empyema caused by Clostridium bifermentans: A case report.

Edagiz S, Lagace-Wiens P, Embil J, Karlowsky J, Walkty A.

Can J Infect Dis Med Microbiol. 2015 Mar-Apr;26(2):105-7.

29.

Epidemiology of vancomycin-resistant enterococci in Canadian hospitals (CANWARD study, 2007 to 2013).

Simner PJ, Adam H, Baxter M, McCracken M, Golding G, Karlowsky JA, Nichol K, Lagacé-Wiens P, Gilmour MW; Canadian Antimicrobial Resistance Alliance (CARA), Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2015 Jul;59(7):4315-7. doi: 10.1128/AAC.00384-15. Epub 2015 Apr 20.

30.

Pasteurella species peritoneal dialysis-associated peritonitis: Household pets as a risk factor.

Poliquin PG, Lagacé-Wiens P, Verrelli M, Allen DW, Embil JM.

Can J Infect Dis Med Microbiol. 2015 Jan-Feb;26(1):52-5. Review.

31.

Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.

Zhanel GG, Love R, Adam H, Golden A, Zelenitsky S, Schweizer F, Gorityala B, Lagacé-Wiens PR, Rubinstein E, Walkty A, Gin AS, Gilmour M, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2015 Feb;75(3):253-70. doi: 10.1007/s40265-015-0352-7. Review.

PMID:
25673021
32.

Changing trends in β-hemolytic streptococcal bacteremia in Manitoba, Canada: 2007-2012.

Schwartz IS, Keynan Y, Gilmour MW, Dufault B, Lagacé-Wiens P.

Int J Infect Dis. 2014 Nov;28:211-3. doi: 10.1016/j.ijid.2014.03.1376. Epub 2014 Oct 18.

33.
34.

Interim estimates of 2013/14 influenza clinical severity and vaccine effectiveness in the prevention of laboratory-confirmed influenza-related hospitalisation, Canada, February 2014.

McNeil S, Shinde V, Andrew M, Hatchette T, Leblanc J, Ambrose A, Boivin G, Bowie W, Diaz-Mitoma F, Elsherif M, Green K, Haguinet F, Halperin S, Ibarguchi B, Katz K, Langley J, Lagace-Wiens P, Light B, Loeb M, McElhaney J, Mackinnon-Cameron D, McCarthy A, Poirier M, Powis J, Richardson D, Semret M, Smith S, Smyth D, Stiver G, Trottier S, Valiquette L, Webster D, Ye L, McGeer A; Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) Serious Outcomes Surveillance Network; Toronto Invasive Bacterial Diseases Network (TIBDN).

Euro Surveill. 2014 Mar 6;19(9). pii: 20729.

35.

Hemorrhagic pustules in an Aboriginal man.

MacDonald K, Lagacé-Wiens P, Embil J.

CMAJ. 2014 May 13;186(8):607-10. doi: 10.1503/cmaj.131328. Epub 2014 Mar 3. Review. No abstract available.

36.

In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012.

Walkty A, Adam H, Baxter M, Denisuik A, Lagacé-Wiens P, Karlowsky JA, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2014 May;58(5):2554-63. doi: 10.1128/AAC.02744-13. Epub 2014 Feb 18.

37.

Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections.

Lagacé-Wiens P, Walkty A, Karlowsky JA.

Core Evid. 2014 Jan 24;9:13-25. doi: 10.2147/CE.S40698. eCollection 2014. Review.

38.

Evaluation of MRSASelect (™) chromogenic medium for the early detection of methicillin-resistant Staphylococcus aureus from blood cultures.

Manickam K, Walkty A, Lagacé-Wiens PR, Adam H, Swan B, McAdam B, Pieroni P, Alfa M, Karlowsky JA.

Can J Infect Dis Med Microbiol. 2013 Winter;24(4):e113-6.

39.

A case of vertical transmission of Chagas disease contracted via blood transfusion in Canada.

Fearon MA, Scalia V, Huang M, Dines I, Ndao M, Lagacé-Wiens P.

Can J Infect Dis Med Microbiol. 2013 Spring;24(1):32-4.

40.

Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.

Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, Lagacé-Wiens PR, Rubinstein E, Gin AS, Walkty A, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2014 Jan;74(1):31-51. doi: 10.1007/s40265-013-0168-2. Review.

PMID:
24352909
41.

In Vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARD surveillance study.

Karlowsky JA, Denisuik AJ, Lagacé-Wiens PR, Adam HJ, Baxter MR, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2014;58(2):1252-6. doi: 10.1128/AAC.02399-13. Epub 2013 Dec 9.

42.

Novel fastidious, partially acid-fast, anaerobic Gram-positive bacillus associated with abscess formation and recovered from multiple medical centers.

Harrington SM, Bell M, Bernard K, Lagacé-Wiens P, Schuetz AN, Hartman B, McQuiston JR, Wilson D, Lasalvia M, Ng B, Richter S, Taege A.

J Clin Microbiol. 2013 Nov;51(11):3903-7. doi: 10.1128/JCM.01497-13. Epub 2013 Sep 11.

43.

In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study.

Karlowsky JA, Adam HJ, Baxter MR, Lagacé-Wiens PR, Walkty AJ, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2013 Nov;57(11):5600-11. doi: 10.1128/AAC.01485-13. Epub 2013 Aug 26.

44.

In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012.

Walkty A, Karlowsky JA, Adam H, Baxter M, Lagacé-Wiens P, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2013 Nov;57(11):5707-9. doi: 10.1128/AAC.01404-13. Epub 2013 Aug 12.

45.

Successful treatment of pulmonary blastomycosis with continuously infused amphotericin B deoxycholate after failure with liposomal amphotericin B.

Ariano RE, Mitchelmore BR, Lagacé-Wiens PR, Zelenitsky SA.

Ann Pharmacother. 2013 Jun;47(6):e26. doi: 10.1345/aph.1R703. Epub 2013 May 14.

PMID:
23673538
46.

Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study.

Zhanel GG, Adam HJ, Baxter MR, Fuller J, Nichol KA, Denisuik AJ, Lagacé-Wiens PR, Walkty A, Karlowsky JA, Schweizer F, Hoban DJ; Canadian Antimicrobial Resistance Alliance.

J Antimicrob Chemother. 2013 May;68 Suppl 1:i7-22. doi: 10.1093/jac/dkt022.

PMID:
23587781
47.

Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11.

Denisuik AJ, Lagacé-Wiens PR, Pitout JD, Mulvey MR, Simner PJ, Tailor F, Karlowsky JA, Hoban DJ, Adam HJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance.

J Antimicrob Chemother. 2013 May;68 Suppl 1:i57-65. doi: 10.1093/jac/dkt027.

PMID:
23587779
48.

Changing epidemiology of methicillin-resistant Staphylococcus aureus in Canada.

Nichol KA, Adam HJ, Roscoe DL, Golding GR, Lagacé-Wiens PR, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance.

J Antimicrob Chemother. 2013 May;68 Suppl 1:i47-55. doi: 10.1093/jac/dkt026.

PMID:
23587778
49.

Changes in fluoroquinolone resistance over 5 years (CANWARD 2007-11) in bacterial pathogens isolated in Canadian hospitals.

Karlowsky JA, Adam HJ, Desjardins M, Lagacé-Wiens PR, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance.

J Antimicrob Chemother. 2013 May;68 Suppl 1:i39-46. doi: 10.1093/jac/dkt025.

PMID:
23587777
50.

Comparison of pathogens and their antimicrobial resistance patterns in paediatric, adult and elderly patients in Canadian hospitals.

Adam HJ, Baxter MR, Davidson RJ, Rubinstein E, Fanella S, Karlowsky JA, Lagacé-Wiens PR, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

J Antimicrob Chemother. 2013 May;68 Suppl 1:i31-7. doi: 10.1093/jac/dkt024.

PMID:
23587776

Supplemental Content

Loading ...
Support Center